Submission on Behalf of the British Geriatrics Society to the National Institute for Clinical Excellence Health Technology Appraisal: Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer’s Disease

  • Published 2010

Abstract

Alzheimer’s disease (AD) is the most common cause of dementia and is a progressive neurodegenerative illness for which at present there is no cure. The management involves both nonpharmacological and pharmacological approaches. This submission will concentrate mostly on the acetylcholinesterase inhibitors (AChEI), donepezil, rivastigmine and galantamine as… (More)

Topics

  • Presentations referencing similar topics